Regulatory Milestone Offers Hope for Rare Disease Community
For the rare disease and genetic condition community, regulatory pathways represent critical turning points in the journey from laboratory innovation to patient access. Recent updates from Regenxbio regarding its gene therapy candidate for Hunter syndrome highlight important developments in how regulatory bodies engage with rare disease developers.
According to reports from The Pharma Letter, Regenxbio announced that the U.S. Food and Drug Administration (FDA) has cleared a path for the resubmission of its Biologics License Application (BLA) for NAVSUNLI (clemidsogene lanparvovec-sngl, RGX-121), an investigational one-time gene therapy for Hunter syndrome (Mucopolysaccharidosis Type II). Following an appeal of a complete response letter issued in February 2026, the company stated that it is now aligned with regulators on the steps required for a potential accelerated approval.
Crucially, the FDA acknowledged that existing clinical data is sufficient for consideration under the accelerated approval pathway. Regulators confirmed that Regenxbio does not need to enroll additional patients or conduct new clinical studies, such as adding an untreated control arm.
What This Means for Patients and Families
Developments in gene therapy evaluation pathways carry broad implications for individuals and families affected by severe genetic conditions. For communities navigating ultra-rare neurodegenerative disorders, efficient regulatory reviews using established biomarker and clinical data can significantly impact timelines for potential therapeutic options.
Looking Ahead
Regenxbio reported plans to request a Type A meeting with the FDA in July to review longer-term biomarker and clinical data. Following this meeting, the company expects to resubmit its BLA for NAVSUNLI in the third quarter of 2026, with the agency committing to an expedited review process.